TrialSignal
Clinical trial intelligence report
A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01027598
Status
COMPLETED
Phase
Phase II
Sponsor
SCRI Development Innovations, LLC
Executive brief
Investment-Ready Snapshot
This trial evaluated the efficacy of combining erlotinib with pazopanib versus erlotinib alone in patients with previously treated advanced NSCLC. The study aimed to improve progression-free survival (PFS) by targeting both EGFR and VEGFR pathways.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01027598
Indication
Non Small Cell Lung Cancer
Modality
small molecule
Target
Non-Small Cell Lung Cancer (NSCLC)
Intervention
Pazopanib, Erlotinib
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.